1. Home
  2. OI vs ADPT Comparison

OI vs ADPT Comparison

Compare OI & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo O-I Glass Inc.

OI

O-I Glass Inc.

HOLD

Current Price

$10.80

Market Cap

2.3B

ML Signal

HOLD

Logo Adaptive Biotechnologies Corporation

ADPT

Adaptive Biotechnologies Corporation

HOLD

Current Price

$14.21

Market Cap

2.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
OI
ADPT
Founded
1903
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Containers/Packaging
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.3B
2.0B
IPO Year
1994
2019

Fundamental Metrics

Financial Performance
Metric
OI
ADPT
Price
$10.80
$14.21
Analyst Decision
Buy
Strong Buy
Analyst Count
7
9
Target Price
$16.86
$17.78
AVG Volume (30 Days)
2.5M
1.9M
Earning Date
04-28-2026
04-30-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
63.89
EPS
N/A
N/A
Revenue
$6,426,000,000.00
$276,976,000.00
Revenue This Year
$2.96
$3.98
Revenue Next Year
$1.86
$22.72
P/E Ratio
N/A
N/A
Revenue Growth
N/A
54.77
52 Week Low
$9.23
$6.68
52 Week High
$16.91
$20.76

Technical Indicators

Market Signals
Indicator
OI
ADPT
Relative Strength Index (RSI) 35.86 44.41
Support Level N/A $12.24
Resistance Level $13.59 $17.52
Average True Range (ATR) 0.45 0.69
MACD 0.06 0.07
Stochastic Oscillator 45.83 58.67

Price Performance

Historical Comparison
OI
ADPT

About OI O-I Glass Inc.

O-I Glass is the world's largest manufacturer of glass bottles; 70% of its revenue comes from outside the United States. O-I has a leading position in key markets such as Europe, North America, and Brazil. Beer is the primary end market for O-I's glass bottles, which are also used for wine, soda, spirits, condiments, and food. O-I is looking to maintain or expand its dominant positions in Europe, North America, and South America.

About ADPT Adaptive Biotechnologies Corporation

Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.

Share on Social Networks: